Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More

News Details

February 06, 2018

DLSS sponsors 2018 Life Sciences Market Access & Commercialization Summit

Today Dohmen Life Science Services helped kick off the 2018 Life Sciences Market Access & Commercialization Summit in Philadelphia, Pa. The conference, organized by World Congress, attracts more than 150 professionals from the rare disease, cell and gene therapy, biosimilars and oncology sectors. Education and networking events will focus on common challenges, new opportunities for innovative product launches, and best practices for payer engagement.

As lead sponsor, Dohmen Life Science Services will be actively involved in leading critical conversations at the event. 


  • Brian Davis, vice president of payer contracting and access, serves as the summit’s Chairperson and will offer insights into market access dynamics on days two and three.
  • Penny Bemus, senior vice president of business development, leads the keynote panel discussion, “Build a Strategy to Ensure Market Access and Commercialization Success in a Healthcare System with Increasing Costs and Complex Therapies.”
  • Linda Newberry-Ferguson, senior vice president, clinical navigation, and Carey Stephenson, director, commercial insights, share “Map the Patient Journey to Enhance Rare Disease Drug Commercialization and Support Better Patient Outcomes.”

For more information, visit World Congress to view the full conference agenda.